Tri Locum Partners
Tri Locum Partners reported 19 stocks worth $813M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are JNJ (13.3%), VRTX (12.3%) and LLY (11.3%). Compared with Q1 2026, the fund opened new positions in ASND, ELVN and RVMD, added to JNJ, VRTX and LLY, trimmed MDGL, UTHR and ISRG and sold out of TMO and ASND.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  JNJ Johnson & Johnson | $108M | 13.3% | 425K | +10K (+3%) | 4 of 8 | |
| 2 |  VRTX Vertex Pharmaceuticals I | $100M | 12.3% | 202K | +72K (+56%) | 2 of 8 | |
| 3 |  LLY Eli Lilly & Co | $91.8M | 11.3% | 77K | +15K (+24%) | 3 of 8 | |
| 4 |  ASND Ascendis Pharma A/s | $69M | 8.5% | 259K | New position | 1 of 8 | |
| 5 |  DXCM Dexcom Inc | $55.3M | 6.8% | 820K | +122K (+18%) | 3 of 8 | |
| 6 |  AXSM Axsome Therapeutics Inc | $53.7M | 6.6% | 219K | +157K (+253%) | 8 of 8 | |
| 7 |  JAZZ Jazz Pharmaceuticals PLC | $53.4M | 6.6% | 222K | +63K (+40%) | 3 of 8 | |
| 8 |  ELVN Enliven Therapeutics Inc | $44M | 5.4% | 867K | New position | 1 of 8 | |
| 9 |  ARGX Argenx SE | $38.6M | 4.8% | 42K | +9,961 (+31%) | 8 of 8 | |
| 10 |  MDGL Madrigal Pharmaceuticals Inc | $36.7M | 4.5% | 68K | −35K (−34%) | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Tri Locum Partners 13F FAQ
What does Tri Locum Partners own?
Tri Locum Partners reported 19 stocks worth $813M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are JNJ (13.3%), VRTX (12.3%) and LLY (11.3%). The table above lists every position in the filing (the top 10 without an account).
What did Tri Locum Partners buy and sell in Q2 2026?
Compared with Q1 2026: 5 new positions, 8 added to, 6 trimmed and 3 sold out. New positions include ASND, ELVN and RVMD. It sold all of TMO and ASND.
When will Tri Locum Partners file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Tri Locum Partners's portfolio worth?
The Q2 2026 filing reports $813M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.